We also found that inhibiting NRF2 with ML385 inhibited the viability of various AML cell lines (Fig. 2g), suggesting that NRF2 and GPX4 could represent promising targets for the treatment of AML cancer cells. This evidence concerns the gene GPX4 and acute myeloid leukemia.